BCL2 and B-cell chronic lymphocytic leukemia: As observed for the KARPAS1718 lines, Bcl-2 expression was induced in primary CLL cells by venetoclax or ixazomib single agent treatment, and most significantly by venetoclax (Fig. 4c, middle).